Introduction
Amyloidosis is an umbrella term encompassing disorders characterized by deposition of fibrils consisting of low-molecular subunits of misfolded normal serum proteins and typically arranged in an antiparallel β-pleated sheet configuration [1] . Primary systemic light-chain amyloidosis is the most common cause of amyloidosis in the western hemisphere [2] . However, primary systemic light-chain amyloidosis is still a rare entity with an estimated annual incidence of only about 3,000 cases in the United States [3] . Biopsy-proven primary systemic light-chain amyloidosis involving the gastrointestinal tract is even rarer [4] . A retrospective review of data collected from patients with all types of amyloidosis showed that only 3.2% had biopsy-proven amyloid involvement of the gastrointestinal tract [5] . The mean age of presentation for primary systemic light-chain amyloidosis is usually in the sixth to seventh decade of life, as evidenced by multiple retrospective studies [5] [6] [7] [8] .
Gastrointestinal involvement in light-chain amyloidosis is defined by the presence of gastrointestinal symptoms with direct biopsy verification of amyloid deposition. The most common symptoms of gastrointestinal amyloidosis include abdominal pain, esophageal reflux, constipation and nausea. The pathophysiology of other symptoms, such as diarrhea, weight loss and early satiety, is much more complex and may include other mechanisms such as autonomic neuropathy, small bowel bacterial overgrowth or cardiac cachexia [5] . We report a rare case of biopsy-proven primary light-chain amyloidosis of the gastrointestinal tract in a much younger woman.
Case Report
A 42-year-old African American woman, born and raised in the United States, presented to the hospital with diarrhea, nausea and intractable vomiting with inability to tolerate oral feeding for 1 week. The patient had multiple prior visits to another institution with similar complaints, where a provisional diagnosis of gastroesophageal reflux disease was made from esophagogastroduodenoscopy. Upon further enquiry, she reported these symptoms to have started more than a year prior to the index presentation. Physical examination at the time of admission revealed a cachectic and disoriented young woman. Other pertinent positive findings of physical examination included hepatomegaly (20 cm) with ascites and bilateral pitting type of pedal edema.
An initial set of laboratory studies showed microcytic, hypochromic anemia (hemoglobin 8.4 g/dl), abnormal coagulation parameters (PT 17.1 s, aPTT 37.1 s), renal dysfunction (BUN 37 mg/dl, serum creatinine 2.0 mg/dl), abnormal liver enzymes (alanine transaminase 51 IU/l, aspartate transaminase 77 IU/l, markedly elevated alkaline phosphatase of 1,655 IU/l with normal bilirubin levels), profound serum hypoalbuminemia (1.5 gm/dl) and nephrotic range of proteinuria (urine dipstick protein assay showed 5+ proteinuria and the spot urine protein/creatinine ratio was 5.7). Additional work-up done for evaluation of abnormal liver enzymes including viral hepatitis panels (hepatitis A, B and C), ANA, anti-smooth muscle antibody, anti-liver kidney microsomal antibodies and antimitochondrial antibody was negative. Serum immunofixation revealed IgG lambda monoclonal protein. Urine immunofixation was negative. An echocardiogram revealed concentric left ventricular hypertrophy with a normal ejection fraction of 78%. A computed tomography scan of the abdomen showed pelvic ascites with mild, diffuse bowel wall thickening.
The patient's hospital course was marked by the persistence of diarrhea with minimal response to presumptive therapy with antibiotics (intravenous metronidazole and oral vancomycin). Stool work-up done for diarrhea revealed no infectious etiology. The patient had deteriorating renal function necessitating renal replacement therapy. She had a selflimited episode of hematemesis.
The patient underwent esophagogastroduodenoscopy and colonoscopy that revealed no gross mucosal lesions. Multiple random biopsies were taken from the stomach, duodenum, terminal ileum, colon and rectum. Biopsy results showed eosinophilic, acellular, globular deposits in the lamina propria and submucosa which stained positively with Congo, consistent with amyloidosis ( fig. 1) . A subsequent bone marrow biopsy revealed normocellular bone marrow with trilineage maturation and diffuse extracellular eosinophilic, amorphous material consistent with amyloidosis ( fig. 2) . A definitive diagnosis of primary systemic light-chain amyloidosis with gastrointestinal tract involvement was made. The patient was not considered for autologous stem cell transplantation, since the outcomes of autologous stem cell transplant in patients with multisystem involvement are often poor and fraught with a high mortality risk. She was subsequently referred to another institution for further management.
Discussion
Our patient presented with multiple symptoms that are prototypical of extensive gastrointestinal involvement from primary systemic amyloidosis. It has been reported that only about 8% of patients have biopsy-proven amyloidosis in the gastrointestinal tract and only about 1% become symptomatic from gastric involvement [4] . The spectrum of symptoms from gastrointestinal amyloidosis is wide, including gastroesophageal reflux disease-like symptoms, nausea and abdominal pain. Symptoms of malabsorption like diarrhea, weight loss and early satiety often result from autonomic neuropathy and small bowel bacterial overgrowth [7, 9, 10] . It has been postulated that severe diarrhea associated with gastrointestinal amyloidosis could also be a result of rapid intestinal transit [11] . The underlying pathology for most of these symptoms is amyloid infiltration and replacement of the intestinal smooth muscle causing dysmotility [12, 13] , which in extreme cases can even present as pseudo-obstruction [8, 12, 14, 15] . Ischemia secondary to vascular infiltration or depletion of ganglion cells has also been noted.
Another constellation of symptoms includes that of gastrointestinal hemorrhage manifesting with hematemesis as seen in our patient, hematochezia and even gastric perforation [16] [17] [18] . Gastrointestinal hemorrhage could be seen in up to 45% of patients with amyloidosis, likely secondary to ischemia, ulceration or generalized mucosal oozing [19] . The finding of a normal endoscopic picture in our patient is unusual, as endoscopic abnormalities such as ulceration and submucosal hematomas were found in nearly 75% of patients with gastrointestinal amyloidosis [20] . The radiological features are varied as well, ranging from subtle bowel wall thickening as seen in our patient ( fig. 1 ) to multiple cystic submucosal masses of the stomach [21] , intestinal pseudo-obstruction and thumbprinting on enteroclysis [8] .
Primary systemic light-chain amyloidosis should be distinguished from other diseases related to deposition of monoclonal light chains, such as noncongophilic light chain deposition disease, and from other forms of systemic amyloidosis. Even as findings of extracellular amorphous material, which is moderately positive for periodic acid-Schiff (PAS) and strongly congophilic, is pathognomonic of amyloidosis, it has been reported that noncalcified psammoma bodies can present as PAS-positive extracellular eosinophilic infiltrates as well [22] . Lipoid proteinosis is another entity characterized by multisystem involvement from deposition of PAS-positive hyaline material in the skin, mucous membranes and internal organs, described in the literature as a disorder with multisystem involvement [23] .
Light-chain amyloidosis is a rare and potentially fatal disease that is most often underdiagnosed. Advances in diagnostic techniques along with use of cardiac biomarkers for staging and free light chains to gauge response have impacted the rates of diagnosis, morbidity and mortality of this disease. The management of primary light-chain amyloidosis is predominantly aimed at elimination of the pathologic plasma cells and thereby the circulating free light chain. This could lead to regression of amyloid deposits, improvement in organ function and offer survival benefit [2] . Autologous stem cell transplantation is an effective and rapid way of achieving clinical response, but only less than a quarter of all patients with primary systemic amyloidosis are candidates for this therapy [24] . Melphalan and dexamethasone regimen became the frontline therapy for patients ineligible for stem cell transplantation [25] . The management of amyloidosis often requires a multidisciplinary approach and close follow-up for long periods of time. This is especially true as it was noted that even in patients with prompt hematologic response, regression of organ damage often takes months to years [2] . 
